234
Views
43
CrossRef citations to date
0
Altmetric
Case Report

Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, & show all
Pages 221-224 | Published online: 06 Apr 2021

References

  • Weycker D, Hanau A, Hatfield M, et al. Immune thrombocytopenia in US clinical practice: incidence and healthcare burden in the first 12 months following diagnosis. J Med Econ. 2020;23(2):184–192. doi:10.1080/13696998.2019.1669329
  • Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55(1):107–111. doi:10.1046/j.1365-2125.2003.01790.x
  • Garbe E, Andersohn F, Bronder E, et al. Drug induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2012;68:821–832. doi:10.1007/s00228-011-1184-3
  • Tseng HF, Sy LS, Quan L. Pneumococcal conjugate vaccine safety in elderly adults. Open Forum Infect Dis. 2018;5(6):1–8.
  • Nagasaki J, Manabe M, Ido K, et al. Postinfluenza vaccination idiopathic thrombocytopenic purpura in three elderly patients. Case Reports in Hematol. Epub 2016 February 21.
  • Jin C, Dong H, Sun Z, et al. Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV). Hum Vaccin Immunother. 2013;9(8):1739–1740. doi:10.4161/hv.24847
  • Genovese C, La Fauci V, Squeri A, Trimarchi G, Squeri R. HPV vaccine and autoimmune diseases: systematic review and metaanalysis of the literature. J Prev Med Hyg. 2018;59:E194–E199. doi:10.15167/2421-4248/jpmh2018.59.3.998
  • Miller E, Waight P, Farrington P, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84:227–229. doi:10.1136/adc.84.3.227
  • Cecinati V, Principi N, Brescia L. Vaccine administration and the development of immune thrombocytopenic purpura in children. Human Vacc Immunotherap. 2013;9(5):1158–1162. doi:10.4161/hv.23601
  • France EK, Glanz J, Xu S, et al.; Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121(3):e687–e92. doi:10.1542/peds.2007-1578
  • Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: eudraVigilance data and literature review. Vaccine. 2012;30(49):7123–7129. doi:10.1016/j.vaccine.2012.09.032
  • Centers for disease control and prevention.. Available from: https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed February. 15, 2021
  • Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA. 2020;324(20):2095–2096. doi:10.1001/jama.2020.20892
  • Leopold V, Pereverzeva L, Schuurman AR, et al. Platelets are hyperactivated but show reduced glycoprotein VI reactivity in COVID-19 patients. Thromb Haemost. 2021. doi:10.1055/a-1347-5555
  • Comer SP, Cullivan S, Sklanna PB, et al. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol. 2021;19(2):e3001109. doi:10.1371/journal.pbio.3001109
  • Slomka A, Kowalewski M, Zekanowska E. Coronavirus disease 2019 (COVID-19): a short review on hematological manifestations. Pathogens. 2020;9(6):493. doi:10.3390/pathogens9060493
  • Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Comp Clin Med. 2020;2:2048–2058. doi:10.1007/s42399-020-00521-8
  • Giordano P, Cascioli S, Lassandro G, et al. B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy. Ped Res. 2016;79(2):262–270. doi:10.1038/pr.2015.211
  • Yokomichi H, Tanaka-Taya K, Koshida R, et al. Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case-control study. Int J Hematol. 2020;112(1):105–114. doi:10.1007/s12185-020-02866-1
  • Vaccine adverse event reporting system. Available from: https://vaers.hhs.gov. Accessed February 15, 2021.
  • Tarawneh OH, Tarawneh HS. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. 2021. doi:10.1002/ajh.26106
  • Kuter DJ, Bussel JB, Lyons RM, et al. Randomized, controlled, 6-month evaluation of AMG-531 in patients with chronic immune thrombocytopenic Purpura. Lancet. 2008;371(9610):395–403. doi:10.1016/S0140-6736(08)60203-2
  • Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628–638. doi:10.1016/j.clpt.2004.08.010
  • Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J of Cut Med Surg. 2019;21(1):50–74. doi:10.1177/1203475418811335
  • Tarantino MD, Chalmers S. Therapeutic Thrombopoietin Mimetics. In: Gresele P, Kleiman NS, Lopez JA, Page CP, editors. Platelets in Thrombotic and Nonthrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics, 2nd. Cambridge University Press; 2016: 1417–1429.
  • Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Brit J of Haematol. 2013;161:411–423. doi:10.1111/bjh.12260
  • Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Brit J of Haematol. 2020;189(6):1038–1043. doi:10.1111/bjh.16775